CClinicalTrials.gg
RecruitingNCT07599696Updated May 20, 2026

Speech Amplification Devices for Parkinson Disease: Talker- and Technology-Driven Enhancements

An interventional study of Behavioral speech strategies + speech amplification in Parkinson Disease and Atypical Parkinsonism, sponsored by Michigan State University. Recruiting at 1 site in United States. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-05-20.

Sponsored by Michigan State University · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Not applicable
Ages
50 Years and older
Sex
All
01

Study summary

The proposed research aims to investigate the use of speech amplification devices as a potential treatment option for people with Parkinson's disease and related disorders who exhibit hypophonia, a voice disorder that affects over half of those with Parkinson's disease. By characterizing the acoustic and perceptual effects of speech amplification and identifying ways to optimize outcomes through talker- and device-specific enhancements, this project seeks to develop personalized, evidence-based treatment options for hypophonia. The current proposal will move this effort forward by systematically eliciting and modifying speech amplification device output that leverage both behavioral and technological approaches.

Read the detailed description

Though intensive behavioral speech intervention is considered the "gold standard" for treating hypophonia in Parkinson's disease (PD), many individuals struggle to transfer or maintain these behavioral strategies into their daily communication. This is because PD, affecting over six million people worldwide, is a progressive, neurodegenerative disorder that also impairs cognition, sensorimotor integration, and fatigue. Speech amplification devices are a type of augmentative technology that have been shown to improve communication related outcomes in PD. Amplification devices increase the volume of a person's natural speech and can be used on their own or to augment behavioral speech outcomes. The specific acoustic mechanisms underlying these benefits are unknown, though previous evidence suggests that increased signal intensity alone is not responsible for improved auditory-perceptual outcomes. The overall goal of this proposal is to identify the relationship between acoustic and perceptual consequences of amplification devices with and without the use of behavioral speech strategies. Aim 1 of this proposal will quantify the acoustic and auditory-perceptual effects of speech amplification devices for talkers with PD. In addition to using an amplification device, participants will speak with both their habitual speech style and a hyperarticulated, clear speech style. Aim 2 will identify the contribution of resultant acoustic features as well as targeted acoustic enhancements that optimize intelligibility in amplified speech. Acoustic modifications that impact the relative contributions of low to high frequency spectral energy will be made to a subset of the speech recordings from Aim 1. These acoustic enhancements will serve to simulate potential technological improvements to amplification devices. Naïve listeners will hear the speech recordings made in Aims 1 and 2 and will provide measures of listener accuracy and effort. Improvements in speech intelligibility of amplified speech are hypothesized to be associated with acoustic measures that reflect relative greater high to low frequency components of the speech signal. The most positive change is hypothesized to occur when talkers combine behavioral speech strategies with amplification compared to behavioral changes or amplified speech alone. Furthermore, auditory-perceptual outcomes are hypothesized to improve following implementation signal enhancements that could be directly integrated into future amplification device development. Collectively, this study will identify ways to maximize speech treatment outcomes of speech amplification devices through behavioral changes made by the talker or acoustic enhancements to the device output itself. Results will guide behavioral treatment strategies and future device modifications that will improve the efficacy of speech amplifiers in this population. This work is innovative for establishing ways to leverage behavioral speech strategies with advances in augmentative technology for PD. It is theoretically significant for defining the role of spectral acoustics in auditory-perceptual outcomes in disordered speech. It is clinically significant for advancing patient-centered augmentative speech treatment technology for PD.

02

Conditions studied

  • Parkinson Disease
  • Atypical Parkinsonism

Keywords

  • speech
  • Parkinson's disease
  • atypical parkinsonism
  • speech acoustics
  • speech-language pathology
  • hypophonia
  • voice
  • voice disorders
  • speech disorders
  • dysarthria
03

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Dominant speakers of North American English
  • Have received a neurologist's diagnosis of Parkinson disease or parkinsonism (e.g., PSP/MSA/PSP)
  • Present with changes in their speech/voice

Exclusion criteria

Exclusion Criteria:

  • History of any other speech, language, or neurological concern other than Parkinson/parkinsonism.
  • Uncorrected hearing loss that exceeds a threshold of 40 dB HL in more than one ear (as per baseline screening audiometry) and/or use of a cochlear implant.
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Speech Study

    Single arm study: All speech conditions are administered.

    Behavioral: Behavioral speech strategies + speech amplification

Interventions

  • BehavioralBehavioral speech strategies + speech amplification

    Behavioral speech strategies + speech amplification

05

What researchers measure

Primary outcomes

  1. Speech intensity

    Decibel sound pressure level (dB SPL) measured from speech audio recordings

    Time frame: Day 1

  2. Voice quality

    Cepstral peak prominence smoothed (CPPS), measured in decibels (dB) from speech audio recordings

    Time frame: Day 1

  3. Articulation

    Quadrilateral vowel articulation index, measured as a composite of first and second formants in Herz (Hz) across four vowels in speech audio recordings.

    Time frame: Day 1

Secondary outcomes

  1. Speech intelligibility

    % words correctly understood by naive listeners (0% = no words correctly transcribed; 100% = all words correctly transcribed). Listener participants transcribe speech recorded by speaker participants.

    Time frame: From end of speech study enrollment to within 1 year. Perceptual measures are elicited from naive listeners following the speech recording study.

  2. Perceived Listener Effort

    % along a visual analogue scale (0 = "no effort required to understand the speech"; 100 = "maximal effort required to understand the speech"). Listener participants will rate speech recorded by speaker participants.

    Time frame: From end of speech study enrollment to within 1 year. Listener effort will be elicited from naive listeners following the speech recording study.

06

Study locations

1 of 1 sites recruiting
  • Michigan State University
    East Lansing, Michigan 48823, United States
    • Thea Knowles, PhD · Contact · thea@msu.edu · 517-353-6401
    • Thea Knowles, PhD · Principal investigator
    Recruiting
07

References and documents

Study documents

  • Informed consent form · Apr 3, 2026

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: Undecided

08

Registry details

Key details

Study ID
NCT07599696
Lead sponsor
Michigan State University
Collaborators
National Institute on Deafness and Other Communication Disorders (NIDCD)
Responsible party
Thea Knowles (Assistant Professor, Michigan State University) — Principal investigator
First posted
May 20, 2026
Start date
Mar 1, 2024
Primary completion
Dec 31, 2027 (estimated)
Completion
May 31, 2028 (estimated)
Last update
May 20, 2026

Study contacts

Thea Knowles, PhD
Contact
thea@msu.edu
517-353-6401

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion